Kineta
Kineta
KA
NASDAQ
0.33
USD
-2.94%
About
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity.
Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma.
It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 59.5K |
| Three Month Average Volume | 15.5M |
| High Low | |
| Fifty-Two Week High | 5.39 USD |
| Fifty-Two Week Low | 0.3339 USD |
| Fifty-Two Week High Date | 03 Oct 2023 |
| Fifty-Two Week Low Date | 16 Apr 2024 |
| Price and Volume | |
| Current Price | 0.64 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | 7.79% |
| Thirteen Week Relative Price Change | 28.68% |
| Twenty-Six Week Relative Price Change | -34.67% |
| Fifty-Two Week Relative Price Change | -74.33% |
| Year-to-Date Relative Price Change | -85.11% |
| Price Change | |
| One Day Price Change | -0.22% |
| Thirteen Week Price Change | 37.72% |
| Twenty-Six Week Price Change | -28.17% |
| Five Day Price Change | 1.59% |
| Fifty-Two Week Price Change | -67.84% |
| Year-to-Date Price Change | -82.37% |
| Month-to-Date Price Change | 6.67% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.27796 USD |
| Book Value Per Share (Most Recent Quarter) | -0.66378 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.27796 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.66378 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.45856 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.49231 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.27547 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.7925 USD |
| Normalized (Last Fiscal Year) | -1.27547 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.27547 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.7925 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.27547 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.7925 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.55622 USD |
| Cash Per Share (Most Recent Quarter) | 0.07343 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.27257 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.76083 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.80666 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -570 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -258.65% |
| Pretax Margin (5 Year) | -854.74% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -288.92% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -773.03% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -258.65% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -854.74% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -75.50% |
| Tangible Book Value (5 Year) | -52.08% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | 13.89% |
| Revenue Change (Trailing Twelve Months) | -100.00% |
| Revenue Per Share Growth | -45.59% |
| Revenue Growth (5 Year) | -7.59% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -613.31% |
| EPS Change (Trailing Twelve Months) | -1.41% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -271,000 |
| Net Debt (Last Fiscal Year) | -5,013,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 5 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -16,209,000 |
| Free Cash Flow (Trailing Twelve Months) | -9,538,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -1,310 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 27 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -101.57% |
| Return on Assets (Trailing Twelve Months) | -220.35% |
| Return on Assets (5 Year) | -66.16% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -385.53% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -110.63% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -318.39% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -86.61% |